Reports of Biochemistry

Mendeley  

Zotero  

Esmaili M A, Kazemi A, Zaker F, Faranoush M, Rezvany M R. Effects of Reduced Mir-24 Expression on Plasma Methotrexate Levels, Therapy-Related Toxicities,and Patient Outcomes in Pediatric Acute Lymphoblastic Leukemia. rbmb.net 2020; 8 (4) :358-365
URL: http://rbmb.net/article-1-378-en.html

Background: The current study aims to investigate the relationship of miR-24 expression with plasma methotrexate (MTX) levels, therapy-related toxicities, and event-free survival (EFS) in Iranian pediatric acute lymphoblastic leukemia (ALL) patients.
Methods: The study included 74 ALL patients in consolidation phase and 41 healthy children. RNA was extracted from plasma, polyadenylated, and reverse transcribed. miR-24 expression was determined by quantitative polymerase chain reaction (qPCR). Plasma MTX concentrations were measured by high performance liquid chromatography (HPLC) 48 h after high-dose methotrexate (HD-MTX) injection. The diagnosis of ALL was further subclassified as B-ALL or T-ALL via flow cytometry.
Results: miR-24 expression was less in pediatric ALL patients than in the control group (p = 0.0038). Furthermore, downregulation of miR-24 was correlated with intermediate-to high-grade HD-MTX therapy toxicities (p = 0.025). Nevertheless, no statistically significant associations were seen between miR-24 levels and plasma MTX levels 48 h after HD-MTX administration (p > 0.05) or EFS in pediatric ALL patients (p > 0.05).
Conclusions: miR-24 expression may contribute to interindividual variability in response to intermediate-to high-grade HD-MTX therapy toxicities under Berlin Frankfurt Munster (BFM) treatment.